FDA Approves Bijuva: A New Oral Bioidentical Of Estrogen and Progesterone
Posted on October 30, 2018
Source:
TherapeuticsMD
TherapeuticsMD announces FDA approval of TX-001HR: BIJUVA™ (estradiol and progesterone) capsules for the treatment of moderate to severe vasomotor symptoms due to menopause.
BIJUVA is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus. BIJUVA is expected to be available in pharmacies in the second quarter of 2019.